Literature DB >> 35595983

Cardiovascular risk in patients receiving antihypertensive drug treatment from the perspective of endothelial function.

Tatsuya Maruhashi1, Yukihito Higashi2,3.   

Abstract

Blood-pressure-lowering therapy with antihypertensive drugs can reduce the risk of cardiovascular morbidity and mortality in patients with hypertension. However, patients treated with antihypertensive drugs generally have a worse prognosis than untreated individuals. Consistent with the results obtained from epidemiological studies, a clinical study showed that endothelial function was impaired more in treated patients with hypertension than in untreated individuals with the same blood pressure level, suggesting that blood-pressure-lowering therapy with currently available antihypertensive drugs cannot restore endothelial function to the level of that in untreated individuals. Several mechanisms of endothelial dysfunction in treated patients are postulated: irreversible damage to the endothelium caused by higher cumulative elevated blood pressure exposure over time; the persistence of the primary causes of hypertension even after the initiation of antihypertensive drug treatment, including an activated renin-angiotensin-aldosterone system, oxidative stress, and inflammation; and higher global cardiovascular risk related not only to conventional cardiovascular risk factors but also to undetectable nonconventional risk factors. Lifestyle modifications/nonpharmacological interventions should be strongly recommended for both untreated and treated individuals with hypertension. Lifestyle modifications/nonpharmacological interventions may directly correct the primary causes of hypertension, which can improve endothelial function and consequently reduce cardiovascular risk regardless of the use or nonuse of antihypertensive drugs.
© 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.

Entities:  

Keywords:  Antihypertensive drug treatment; Cardiovascular risk; Endothelium-dependent vasodilation; Flow-mediated vasodilation; Hypertension

Mesh:

Substances:

Year:  2022        PMID: 35595983     DOI: 10.1038/s41440-022-00936-x

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   5.528


  77 in total

1.  Cardiovascular protection and blood pressure reduction: a meta-analysis.

Authors:  J A Staessen; J G Wang; L Thijs
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

Review 2.  Regulatory functions of the vascular endothelium.

Authors:  J R Vane; E E Anggård; R M Botting
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

Review 3.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

4.  Cardiovascular risk with and without antihypertensive drug treatment in the Japanese general population: participant-level meta-analysis.

Authors:  Kei Asayama; Michihiro Satoh; Yoshitaka Murakami; Takayoshi Ohkubo; Sin-Ya Nagasawa; Ichiro Tsuji; Takeo Nakayama; Akira Okayama; Katsuyuki Miura; Yutaka Imai; Hirotsugu Ueshima; Tomonori Okamura
Journal:  Hypertension       Date:  2014-03-17       Impact factor: 10.190

5.  Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man.

Authors:  P Vallance; J Collier; S Moncada
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

6.  Endothelial Function Is Impaired in Patients Receiving Antihypertensive Drug Treatment Regardless of Blood Pressure Level: FMD-J Study (Flow-Mediated Dilation Japan).

Authors:  Tatsuya Maruhashi; Junko Soga; Noritaka Fujimura; Naomi Idei; Shinsuke Mikami; Yumiko Iwamoto; Akimichi Iwamoto; Masato Kajikawa; Takeshi Matsumoto; Nozomu Oda; Shinji Kishimoto; Shogo Matsui; Haruki Hashimoto; Yoshiki Aibara; Farina Binti Mohamad Yusoff; Takayuki Hidaka; Yasuki Kihara; Kazuaki Chayama; Kensuke Noma; Ayumu Nakashima; Chikara Goto; Hirofumi Tomiyama; Bonpei Takase; Takahide Kohro; Toru Suzuki; Tomoko Ishizu; Shinichiro Ueda; Tsutomu Yamazaki; Tomoo Furumoto; Kazuomi Kario; Teruo Inoue; Shinji Koba; Kentaro Watanabe; Yasuhiko Takemoto; Takuzo Hano; Masataka Sata; Yutaka Ishibashi; Koichi Node; Koji Maemura; Yusuke Ohya; Taiji Furukawa; Hiroshi Ito; Hisao Ikeda; Akira Yamashina; Yukihito Higashi
Journal:  Hypertension       Date:  2017-08-14       Impact factor: 10.190

7.  Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.

Authors:  Weili Zhang; Shuyuan Zhang; Yue Deng; Shouling Wu; Jie Ren; Gang Sun; Jinfeng Yang; Yinong Jiang; Xinjuan Xu; Tzung-Dau Wang; Youren Chen; Yufeng Li; Lianchen Yao; Dianfang Li; Lixin Wang; Xiaomei Shen; Xinhua Yin; Wei Liu; Xiaoyang Zhou; Bingpo Zhu; Zihong Guo; Hualing Liu; Xiaoping Chen; Yingqing Feng; Gang Tian; Xiuyin Gao; Kazuomi Kario; Jun Cai
Journal:  N Engl J Med       Date:  2021-08-30       Impact factor: 91.245

8.  Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis.

Authors:  Joshua D Bundy; Changwei Li; Patrick Stuchlik; Xiaoqing Bu; Tanika N Kelly; Katherine T Mills; Hua He; Jing Chen; Paul K Whelton; Jiang He
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

9.  Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study.

Authors:  J Blacher; A Evans; D Arveiler; P Amouyel; J Ferrières; A Bingham; J Yarnell; B Haas; M Montaye; J-B Ruidavets; P Ducimetière
Journal:  J Hum Hypertens       Date:  2010-01       Impact factor: 3.012

10.  Adult mortality attributable to preventable risk factors for non-communicable diseases and injuries in Japan: a comparative risk assessment.

Authors:  Nayu Ikeda; Manami Inoue; Hiroyasu Iso; Shunya Ikeda; Toshihiko Satoh; Mitsuhiko Noda; Tetsuya Mizoue; Hironori Imano; Eiko Saito; Kota Katanoda; Tomotaka Sobue; Shoichiro Tsugane; Mohsen Naghavi; Majid Ezzati; Kenji Shibuya
Journal:  PLoS Med       Date:  2012-01-24       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.